Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 8/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL888160 | 0.92 | SLC29A1 (0.44) | SLC29A1ADORA3CYP1A2HPGD | |
| SCHEMBL888259 | 0.91 | SLC29A1 (0.46) | SLC29A1ADORA3CYP1A2HPGD | |
| SCHEMBL1514925 | 0.86 | SLC29A1 (0.39) | SLC29A1ADORA3CYP1A2HPGD | |
| SCHEMBL889534 | 0.85 | SLC29A1 (0.48) | SLC29A1ADORA3CYP1A2HPGD | |
| SCHEMBL14788954 | 0.85 | SLC29A1 (0.48) | SLC29A1ADORA3CYP1A2HPGD | |
| SCHEMBL12570164 | 0.84 | SLC29A1 (0.47) | SLC29A1ADORA3CYP1A2HPGD | |
| SCHEMBL1140221 | 0.83 | ADORA3 (0.47) | SLC29A1ADORA3 | |
| SCHEMBL1140519 | 0.81 | SLC29A1 (0.43) | SLC29A1ADORA3CYP1A2 | |
| SCHEMBL888130 | 0.79 | CHKA (0.34) | — | |
| SCHEMBL889591 | 0.76 | SLC29A1 (0.67) | SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110287427-A1 | 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7897737-B2 | Polymorphic identification; fluorescent dyes | LASERGEN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | AGILENT TECHNOLOGIES, INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | UNG, DCLRE1B, NT5C3B | SLC29A1 213/4885ADORA3 113/4885CYP1A2 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.